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Objectives: The aim of this study was to measure blood concentrations of environ-
mental pollutants in Norwegian donors and evaluate the risk of pollutant exposure
through blood transfusions.
Background: Transfused blood may be a potential source of exposure to heavy
metals and organic pollutants and presents a risk to vulnerable patient groups such as
premature infants.
Methods/Materials: Donors were randomly recruited from three Norwegian blood
banks: in Bergen, Tromsø and Kirkenes. Selected heavy metals were measured in whole
blood using inductively coupled plasma mass spectrometry (ICP-MS), and perfluoroalkyl
substances (PFAS)weremeasured in serum by ultrahigh-pressure liquid chromatography
coupledwith a triple-quadrupolemass spectrometer (UHPLC-MS/MS).
Results: Almost 18% of blood donors had lead concentrations over the limit suggested
for transfusions in premature infants (0.09 μmol/L). About 11% of all donors had mer-
cury concentrations over the suggested limit of 23.7 nmol/L. Cadmium was higher than
the limit, 16 nmol/L, in 4% of donors. Perfluorooctanoate (PFOA) and perfluorooctane
sulfonate (PFOS) concentrations were over the suggested limit of 0.91 ng/mL in 68%
and 100% of the donors, respectively. PFAS concentrations and heavy metal concentra-
tions increasedwith donor's age.
Conclusion: A considerable percentage of donors had lead, PFOS and PFOA concentra-
tions over the suggested limits. In addition, at each study site, there were donors with high
mercury and cadmium concentrations. Selecting young donors for transfusions or mea-
surements of pollutants in donor blood may be a feasible approach to avoid exposure
through blood transfusions to vulnerable groups of patients such as premature infants.
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1 | INTRODUCTION
Environmental pollutants are ubiquitous and represent a global threat to
both animals and humans.1-5 The potential for harm is especially great in
periods of life with rapid growth and development, such as during preg-
nancy and childhood. In infants, even low concentrations, transferred
from the mother during pregnancy or by later exposure, may disturb neu-
rological and cognitive development and lead to permanent disabilities.6
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Various measures have been taken to limit human exposure to
environmental pollutants. These include restriction of lead in gasoline,
paint and consumer products by replacing mercury-containing devices
with mercury-free alternatives (eg, in thermometers), by food advi-
sories, by restricting the use of cadmium in electronics and pigments,
by secure waste handling and by other actions to limit emissions to
the environment.7-10 However, the possible transfer of pollutants via
blood transfusions has not been the focus.
During blood transfusions, pollutants present in the donor's blood
are transferred to the recipients. Transfused blood, as well as blood
components, may represent a substantial source of environmental
pollutant exposure for the recipients, particularly for vulnerable
groups such as premature infants who receive multiple blood transfu-
sions.11-14 Blood transfusions were shown to increase heavy metal
concentrations in premature infants.15
Previous published studies have shown that a considerable per-
centage of blood donors have lead concentrations that may cause
concern.16,17 As a result, in some medical institutions, lead testing is
required before transfusions.18-20
Although exposure to lead and other heavy metals has been
addressed, exposure to organic pollutants through donor blood is less
studied. There are few studies of perfluoroalkyl substances (PFAS) in
blood donors.21-24 These studies did not specifically address the risk of
PFAS exposure via blood transfusions to premature infants. Animal stud-
ies showed unfavourable effects of prenatal PFAS exposure, such as low
birthweight, enlarged liver, impaired lung and kidney development and
lipid metabolism changes.25,26 Reduced fetal growth was also demon-
strated in humans after exposure tomixtures of pollutants such as PFAS,
phthalates, lead, mercury, cadmium, thallium and arsenic.27 Studies of
prenatal PFAS exposure in humans showed unfavourable health effects,
such as lower birthweight but greater weight and adiposity later in
life,28-30 increased risk of impaired neuropsychological development in
early childhood31 and increased number of respiratory tract infections in
the first 10 years of life.32
The aim of this multicentre study was to measure blood concen-
trations of lead, cadmium, mercury and PFAS in Norwegian blood
donors and to evaluate the potential risk for pollutant exposure
through blood transfusions with special focus on premature infants.
2 | MATERIALS AND METHODS
2.1 | Ethical approval
The study was approved by the Regional Committee for Medical and
Health Research Ethics, Western Norway. All the participants gave
written informed consent for participation in the study.
2.2 | The study population
Blood donors who were accepted for donation were randomly
selected to participate in the present study. Donors were recruited
from three Norwegian blood banks: in Bergen, Tromsø and Kirkenes.
The rationale for this design was to recruit a representative sample of
Norwegian blood donors from three different geographical regions
in Norway: the Arctic region Finnmark (Kirkenes), Northern Norway
(Tromsø) and Western Norway (Bergen). During the study, all the
blood donors routinely attending the blood banks were consecu-
tively invited to participate in the study, and only one person
refused to participate. No exclusion criteria were applied. As it
was planned in advance, 201 donors were recruited from Bergen,
101 donors from Tromsø and 50 donors from Kirkenes, for a total
of 352 participants. The difference in number of the participants
from different sites reflects the relative size of the population in
these areas. Age, gender and number of previous blood donations
were registered.
2.3 | Analysis of heavy metals
Lead, mercury and cadmium were measured in whole blood using induc-
tively coupled plasmamass spectrometry (ICP-MS) on Perkin Elmer DRC-
e in standard mode (Table Table S1) at the Department of Medical Bio-
chemistry and Pharmacology, Haukeland University Hospital, Bergen.
Limits of quantification (LOQs) for lead, mercury and cadmium were
0.0267 μmol/L, 3.25 nmol/L and 1.615 nmol/L, respectively. Limits of
quantification were defined as five times the within-day analytical
SD. Limits of detection (LODs) were 0.0160 μmol/L for lead, 1.95 nmol/L
formercury and 0.969 nmol/L for cadmium.
The between-run analytical coefficients of variation (CVa) for cad-
mium, mercury and lead were 4.4%, 2.9% and 4.2%, respectively. All
analyses complied with UKNEQAS for trace elements (Royal Surrey
County Hospital, Guildford, UK) and Seronorm Trace Elements Whole
Blood (Sero AS, Billingstad, Norway) acceptable range.
2.4 | Analysis of PFAS
Perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS),
perfluorononane sulfonate (PFNS), perfluorooctanoate (PFOA), per-
fluorononanoate (PFNA) and perfluorodecanoate (PFDA) were
analysed in serum by ultrahigh-pressure liquid chromatography triple-
quadrupole mass-spectrometry (UHPLC-MS/MS, Waters, Milford,
MA, USA) at the Department of Laboratory Medicine, University Hos-
pital of North Norway, Tromsø. The LODs were set as concentrations
calculated by the Targetlynx software for each individual sample
(LODi) and each individual PFAS with a signal to noise ratio of
3, divided by the related sample amount. Mean LODs (SD) were
0.030 ng/mL (0.048 ng/mL) for PFOS, 0.112 ng/mL (0.037 ng/mL)
for PFOA, 0.011 ng/mL (0.006 ng/mL) for PFHxS, 0.014 ng/mL
(0.005 ng/mL) for PFNA and 0.015 ng/mL (0.007 ng/mL) for PFDA.
LOQs for PFAS were defined as three times their LODs. For quality
assurance, four blank samples, four SRM 1958 (NIST, Gaithersburg,
Maryland) and three bovine serum samples (Sigma Aldrich, Steinheim,
Germany) were prepared and analysed within each batch of
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96 samples in order to control for background and carry-over effects.
Details on sample preparation and instrumental analyses were
described earlier.33 All the quality controls were within the acceptance
limits. CVa was <10% for all measured PFAS. All PFAS analyses were
within the acceptable ranges of the international quality control pro-
gramme: the Arctic Monitoring and Assessment (AMAP) Ring Test for
Persistent Organic Pollutants in Human Serum (organised by the
Laboratoire de toxicologie, Institut National de Santé Publique du
Quebec, Canada).
2.5 | Estimation of tolerable intravenous doses
2.5.1 | Lead
The maximum concentration for lead in donor blood given to small
children was set to 0.15 μmol/L (0.031 μg/mL) by Rhainds and
Delage,19 and this limit was later used by various centres.18,20,34 How-
ever, Bearer et al estimated an even lower limit of acceptable lead
concentration of 0.09 μmol/L for intravenous exposure in infants with
extreme low birthweight.11 This threshold was based on the assump-
tion of 10% lead absorption in the gastrointestinal tract and the provi-
sional tolerable weekly intake (PTWI) of 25 μg/kg from the 1996
World Health Organisation (WHO) guidelines for drinking water qual-
ity.35 Given that only 10% of lead is absorbed from the gastrointesti-
nal system, a daily permissible dose would be 0.36 μg/kg; for a donor
unit of 20 mL/kg blood transfusion, the concentration must be less
than 0.018 μg/mL or 0.09 μmol/L.
2.5.2 | Mercury
Whole-blood concentration of mercury in a general population is
usually <50 nmol/L (< 10 ng/mL).36 The US Environmental Protection
Agency (EPA) estimated a maximum daily intake of mercury that
is not likely to cause harmful effects during a lifetime, known as a ref-
erence dose (RdF) for dietary methyl mercury of 0.1 μg/kg/day.37,38
Assuming that about 95% of methylmercury is absorbed from the
gastrointestinal tract, the acceptable limit for mercury will be
0.095 μg/kg/day or 23.7 nmol/L (4.75 ng/mL) for the donor unit of
20 mL/kg.
2.5.3 | Cadmium
In 2011, the European Food Safety Authority (EFSA) defined
2.5 μg/kg/week (22.25 nmol/kg/week) as the tolerable weekly
intake of cadmium, which provides an estimate of a tolerable daily
intake (TDI) of 0.357 μg/kg/day (3.18 nmol/kg/day).39
Based on the conservative assumption that only 10% of the oral
dosage is absorbed, the intravenous tolerable dose would be
0.32 nmol/kg. For a 20 mL/kg transfusion, this corresponds to a
whole-blood cadmium concentration of 16 nmol/L (1.80 ng/mL).
2.5.4 | Selected PFAS
In the 2008 report from the EFSA, the TDI for PFOS was defined as
150 ng/kg/day.40 However, in 2015, the Danish EPA established a
TDI of 30 ng/kg per day for PFOS and a TDI of 100 ng/kg per day
for PFOA.41 PFAS are readily absorbed after dietary exposure with
the highest gastrointestinal uptake estimated as 91%.42 Taking into
consideration the 91% absorption and 20 mL/kg transfusion, a
daily acceptable venous dose for PFOS 1.37 ng/mL and for PFOA
4.55 ng/mL was estimated. In 2016, the US EPA issued a reference
dose (RfD) of 20 ng/kg per day, valid both for PFOS and PFOA.41 If
we use this threshold to calculate a daily acceptable venous dose, it
will be 0.91 ng/mL for 20 mL/kg transfusion for both PFOS and
PFOA. In 2018, the EFSA proposed new tolerable weekly intake (TWI)
oral doses for PFOS and PFOA: 13 and 6 ng/kg/week, respectively.41
If we consider only one transfusion of 20 mL/kg blood per week, then
the tolerable venous dose for PFOS will be 0.59 ng/mL and for PFOA
0.27 ng/mL (the limit will be lower if the number of transfusions
increases). The TDIs for other PFAS, such as PFHxS, PFNA and PFDA,
are not established yet. Therefore, we chose a young and relatively
healthy general Norwegian population without occupational exposure
to PFAS for the comparison. The 97.5 percentile of serum PFHxS,
PFNA and PFDA concentrations measured in Norwegian adolescents
(15-19 years old) from the Fit Futures study were applied as thresh-
olds: 7.66 ng/mL for PFHxS, 1.61 ng/mL for PFNA and 0.79 ng/mL
for PFDA.43
2.6 | Statistical analyses
Statistical analyses were performed using the SPSS programme
(IBM Corp. IBM SPSS Statistics for Windows, Version 24.0., IBM
Corp., Armonk, New York). To reduce possible bias of left-censored
data analyses, we have used the actual values below the LOQs for
both PFAS and heavy metal concentrations. Chi-square test was
used for comparisons of proportions. Spearman correlation was
performed to evaluate associations between various PFAS and
heavy metals. A two-tailed t-test was used to compare age and
number of blood donations between the study sites. Heavy metals
and PFAS concentrations were not normally distributed according
to distribution plots, skewness estimates, QQ-plots and the
Kolmogorov-Smirnov test. Therefore, the non-parametric Mann-
Whitney U test was used for comparisons between the different
study sites. All the heavy metals and PFAS concentrations were
log10-transformed before the statistical analyses because of the
skewed distribution. We have checked the homoscedasticity and
normality of residuals distribution by graphic inspection of residuals
and linearity of the relations between the variables using the
Passing-Bablok test and found that log-transformed concentrations
satisfy these assumptions. Multiple linear regression analyses were
performed for log-transformed concentrations of heavy metals and
PFAS as continuous variables to evaluate associations with age,
gender and number of blood donations. Beta-coefficients were
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back-transformed as 10β to evaluate the associations between the
independent variables and concentrations of pollutants. All statisti-
cal tests were two-sided. A P-value <.05 was considered statisti-
cally significant.
3 | RESULTS
General characteristics of the study population are shown in Table 1.
Blood donors in Kirkenes were slightly older than in Bergen and
Tromsø and had a higher percentage of women. Age and gender dis-
tribution in the entire study population was similar to another study
of the Norwegian donors, with approximately 50% of donors being
women.44 The study population included blood donors of all ages
from three geographic areas in Norway (Arctic, Northern Norway and
Western Norway). The study population included both newly rec-
ruited blood donors with few blood donations and experienced blood
donors with numerous blood donations up to and more than 60 dona-
tions. The mean number of blood donations was similar for all study
sites. We assume that the study population was fairly representative
of the general Norwegian blood donor population.
Concentrations of lead, mercury and cadmium in donor blood are
shown in Table 2. Overall, 4.5% of all blood donors had lead levels
higher than the highest suggested limit for lead concentration in the
TABLE 1 General characteristics of
the study population: The Norwegian
donor study
Bergen Tromsø Kirkenes Entire study
n = 201 n = 101 n = 50 n = 352
Age range, y 19-72 20-66 19-66 19-72
Mean age, y (SD) 43.1 (15.6) 41.4 (12.3) 46.1 (11.1)a 43.0 (14.2)
Mean blood donations (SD) 26.2 (31.2) 26.7 (25.3) 25.2 (20.9) 26.2 (28.2)
Women 47.8% 51.5% 64.0%b 51.1%
0-1 blood donations 13.9% 7.9% 6.1% 11.1%
2-10 blood donations 33.8% 30.7% 26.5% 31.9%
11-20 blood donations 12.0% 17.8% 14.3% 13.9%
21-40 blood donations 15.4% 17.9% 38.8% 19.4%
41-60 blood donations 10.0% 11.9% 8.2% 10.3%
>60 blood donations 14.9% 13.9% 6.1% 13.4%
Note: Two-tailed t-test, Chi-squared test.
aP < .05 compared with Tromsø.
bP < .05 compared with Bergen.
TABLE 2 Concentrations of heavy
metals in blood (μmol/L and nmol/L): The
Norwegian donor study
Bergen Tromsø Kirkenes Entire study
n = 201 n = 101 n = 50 n = 352
Lead, mean (SD), μmol/L 0.068 (0.05) 0.057 (0.03) 0.081 (0.08) 0.067 (0.05)
Lead, median, μmol/L 0.055 0.049 0.062a 0.055
Lead, range, μmol/L <LOD-0.586 <LOD-0.159 <LOD-0.439 <LOD-0.586
Lead >0.15 μmol/L 5.8% 2.0% 6.0% 4.5%
Lead >0.09 μmol/L 10.9% 20.9%b 20.0% 17.9%
Mercury, mean (SD), nmol/L 13.2 (13.5) 12.6 (9.2) 8.73 (6.0) 12.4 (11.7)
Mercury, median, nmol/L 10.2 11.0 7.38a,b 9.49
Mercury, range, nmol/L <LOD-129 <LOD-39.6 <LOD-31.3 <LOD-129
Mercury >50 nmol/L 2.0% 0.0%b 0.0%b 1.1%
Mercury >23.7 nmol/L 11.9% 11.9% 2.0%a,b 10.5%
Cadmium, mean (SD), nmol/L 3.65 (4.04) 2.43 (2.22) 4.94 (4.72) 3.48 (3.80)
Cadmium, median, nmol/L 2.41 1.89b 2.92a 2.30
Cadmium, range, nmol/L <LOD-34.6 <LOD-16.8 <LOD-21.5 <LOD-34.6
Cadmium >16 nmol/L 2.5% 1.0% 4.0% 2.3%
Note: Mann–Whitney U test, Chi-squared test.
aP < .05 compared with Tromsø.
bP < .05 compared with Bergen.
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donor blood (0.15 μmol/L = 0.031 μg/mL), whereas almost 18% of
blood donors had lead concentrations over the alternative limit of
0.09 μmol/L (0.018 μg/mL) suggested for transfusions in premature
infants. Lead concentrations over the limit of 0.09 μmol/L were signif-
icantly more often measured in Tromsø donors than in Bergen donors.
We evaluated age as a possible criterion to select blood with the
lowest lead concentrations. Our calculations showed that the optimal
age cut-off is 22 years or younger, and 0% of donors in this age group
had lead concentrations over the limit 0.09 μmol/L (0.018 μg/mL). If
we used the age cut-off of 40 years or younger, there were 5.2%
donors with lead blood levels over this limit. In the age group of over
40 years, a high lead concentration was found in 28% of donors.
TABLE 3 Associations of heavy
metal blood concentrations with age,
gender and number of blood donations:
The Norwegian donor study (n = 352)
Gender (men vs women) Age (y) Number of blood donations
Heavy metalsa β P-value β P-value β P-value
Lead 1.18 .002 1.02 <.0001 1.00 .69
Mercury 1.15 .093 1.03 <.0001 1.00 .41
Cadmium 0.77 <.0001 1.02 <.0001 1.00 .10
Note: Presented β-coefficients were back-transformed as 10β.
aMultiple linear regression models with log10-transformed heavy metal concentrations as dependent
variables and gender, age and number of blood donations as covariates.
TABLE 4 Concentrations of selected
PFASs in blood (ng/mL): The Norwegian
donor study
Bergen Tromsø Kirkenes Entire study
n = 201 n = 101 n = 50 n = 352
PFOS, mean (SD) 5.71 (3.34) 6.31 (3.68) 5.35 (4.47) 5.83 (3.62)
PFOS, median 4.88 5.27 4.71a 4.91
PFOS, range 1.46-23.8 1.30-19.8 1.75-32.3 1.30-32.3
PFOS > 12.8 ng/mLb 4.0% 5.9% 4.0% 4.5%
PFOS > 1.37 ng/mL 100% 99.0% 100% 99.7%
PFOS > 0.91 ng/mL 100% 100% 100% 100%
PFOS > 0.59 ng/mL 100% 100% 100% 100%
PFOA, mean (SD) 1.41 (0.76) 1.20 (0.56) 1.04 (0.37) 1.30 (0.67)
PFOA, median 1.26 1.08c 0.94c 1.16
PFOA, range 0.48-4.97 0.42-4.15 0.43-2.25 0.42-4.97
PFOA > 4.9 ng/mLb 0.5% 0% 0% 0.3%
PFOA > 4.55 ng/mL 1.0% 0% 0% 0.6%
PFOA > 0.91 ng/mL 72.6% 65.3% 56.0% 68.2%
PFOA > 0.27 ng/mL 100% 100% 100% 100%
PFHxS, mean (SD) 0.87 (1.01) 0.83 (0.63) 0.59 (0.40) 0.82 (0.85)
PFHxS, median 0.64 0.62 0.49a,c 0.62
PFHxS, range 0.15-10.4 0.21-3.72 0.22-2.67 0.15-10.4
PFHxS > 7.66 ng/mLb 0.5% 0% 0% 0.3%
PFNA, mean (SD) 0.60 (0.36) 0.62 (0.30) 0.61 (0.39) 0.61 (0.34)
PFNA, median 0.52 0.52 0.51 0.52
PFNA, range 0.15-2.61 0.17-1.70 0.21-2.66 0.15-2.66
PFNA >1.61 ng/mLb 1.5% 2.0% 2.0% 1.7%
PFDA, mean (SD) 0.27 (0.17) 0.33 (0.21) 0.27 (0.19) 0.29 (0.19)
PFDA, median 0.23 0.25c 0.21 0.24
PFDA, range 0.04-1.16 0.07-1.27 0.08-1.21 0.04-1.27
PFDA >0.79 ng/mLb 2.0% 4.0% 2.0% 2.6%
Note: Mann–Whitney U test. Chi-squared test.
aP < .05 compared with Tromsø.
b97.5 percentile concentration in a young population from Tromsø area (The Fit Futures study).
cP < .05 compared with Bergen.
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Mercury concentrations were not especially high in blood donors:
only 1.1% had mercury concentrations over 50 nmol/L (10 ng/mL).
However, 10.5% of all donors had mercury concentrations over the
suggested limit for donor blood (23.7 nmol/L = 4.75 ng/mL). Donors
from Tromsø and Bergen had significantly higher concentrations of
mercury compared with the donors from Kirkenes. Median and mean
cadmium concentrations were highest in Kirkenes donors (2.92 and
4.94 nmol/L, respectively), of which 4% had concentrations higher
than the suggested limit for donor blood (16 nmol/L = 1.80 ng/mL).
Table 3 shows that lead, mercury and cadmium blood concentra-
tions are significantly positively associated with age. The results of
the regression analyses show that a 1-year increase in age was associ-
ated with a 2% increase of lead and cadmium concentrations and with
a 3% increase of mercury concentration. There was no significant
association between the number of blood donations for lead, mercury
and cadmium. Men had significantly higher concentrations of lead
than women, whereas women had higher concentrations of cadmium.
Lead, mercury and cadmium blood concentrations were significantly
correlated with each other (Table S2). Lead and mercury concentrations
were significantly correlatedwith serumPFAS concentrations (Table S2).
Concentrations of individual PFAS that were measured in donor
serum with a detection frequency of 100% are shown in Table 4. PFAS
concentrations in general were not high in this donor population com-
pared to the 97.5 percentile concentrations derived from the Fit
Futures study of the young general population from Tromsø.43 Only
0.3% to 4.5% of the donors were above 97.5 percentile concentrations
of different PFAS measured in the Fit Futures study of teenagers.43
However, 100% of all donors had PFOS concentrations over the esti-
mated limits of 0.91 and 0.59 ng/mL for the donor blood. About 68%
of all donors had PFOA concentrations above the limit of 0.91 ng/mL
in blood based on the US EPA RfD for oral intake of 20 ng/kg per day.
If the 2018 EFSA TWI limit for PFOA was applied, then 100% of
donors had PFOA concentrations over the limit. Even though these
doses of PFOS and PFOA were lower than the acute cytotoxic doses
(0.1 mg/kg/day), they were over the limits, indicating possible health
effects in humans.41
Concentrations of selected PFAS increased with age (PFOS, PFOA,
PFHxS, PFNA, PFDA) and decreased with number of blood donations
(Table 5). Furthermore, it was observed that men had generally higher
concentrations of PFOS, PFOA, PFHxS and PFNA than women (Table 5).
4 | DISCUSSION
Several publications are suggesting that measures should be taken in
order to limit lead concentrations in donor blood given to premature
infants and small children.12,13,17,45-47 The lead limit of 0.15 μmol/L
used in this study and previously published studies was calculated
from WHO's PTWI and adjusted for bioavailability and other fac-
tors.19 The limit of 0.15 μmol/L for lead was used by several stud-
ies18,34; however, a lower limit of 0.09 μmol/L was suggested for
transfusions in premature infants.11 The lead threshold of 0.09 μmol/L
was discussed in the recent publication in the Nature Pediatric
Research35; no safe concentration of lead was identified, and WHO
had not re-issued the PTWI for lead. The exposure limit based on the
PTWI of 25 μg/kg/week was associated with a significant decrease of
IQ in children.35 The meta-analyses of epidemiological data by the
Joint FAO/WHO Expert Committee on Food Additives showed that a
chronic dietary lead exposure of 0.6 μg/kg/day (4.2 μg/kg/week) cor-
responded to a 1 IQ point decrease in children.48
Lead concentrations in our study were lower than in blood donors
from other countries: median concentration of 0.055 μmol/L (range
0.019-0.586 μmol/L) compared with 0.082 μmol/L (range
0.011-2.90 μmol/L) in Canadian donors.17 In our study, 4.5% of the
blood donors had a blood lead concentration above the limit of
0.15 μmol/L compared to 15.5% in other studies.17 Between 10% and
20% of donors at all of our study sites had lead concentrations over the
limit of 0.09 μmol/L, resulting in the risk of lead exposure to premature
infants and potential harmful effects.
Female donors had higher cadmium concentrations than males.
There is no industry in Norway with occupational exposure to cad-
mium that could explain this gender difference. Studies in other
European populations showed the same gender difference in cad-
mium concentrations and possible association with sex hormones in
women.49,50 Another possible explanation of gender differences in
cadmium concentrations may be different lifestyle and diet habits.
Smoking and diet are known sources of cadmium exposure.49-51 Pop-
ulation studies showed that Norwegian women smoke at least as
much as men.52,53 Unfortunately, we do not have data on smoking
and diet for our study population to test this hypothesis.
All study sites had blood donors with mercury and cadmium con-
centrations above the suggested limits for donor blood. Mercury
TABLE 5 Associations of selected
PFAS serum concentrations with age,
gender and number of blood donations
Gender (men vs women) Age (y) Number of blood donations
PFASa β P-value β P-value β P-value
PFOS 1.75 <.0001 1.02 <.0001 .99 <.0001
PFOA 1.14 .006 1.01 <.0001 .995 <.0001
PFHxS 1.84 <.0001 1.01 <.0001 .99 <.0001
PFNA 1.15 .008 1.02 <.0001 .998 .018
PFDA 1.04 .52 1.02 <.0001 .998 .04
Note: The Norwegian donor study (n = 352).
aMultiple linear regression models with log10-transformed PFAS concentrations as dependent variables
and gender, age and number of blood donations as covariates. Presented β-coefficients were back-
transformed as 10β.
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concentrations over the suggested limit of 23.7 nmol/L (4.75 ng/mL)
were found in 1 of every 10 donors. Prenatal exposure to mercury
was reported to be associated with reduced fetal growth and lower
birthweight,54,55 as well as with adverse effects on neonates' neuro-
behavioral development, poorer language skills at the age of
5 years56,57 and with the increased risk of respiratory infections dur-
ing the first year of life.58 Mercury and lead are identified as one of
the developmental neurotoxicants.5,59 Cadmium exposure was also
reported to be associated with delayed growth in early childhood60
and with adverse effects on neurodevelopment and cognitive function
in children.61,62 Thus, there is emerging evidence that the exposure of
small children to heavy metals may result in cognitive damage.
The present study, as well as previous studies, used heavy metal
limits for donor blood based on the oral TDIs. However, there is a limi-
tation in this approach as the current knowledge indicates that there
are no safe levels for lead63,64 or mercury,65 and for cadmium as well,
the limit for tolerable intake has been challenged.66,67 It has been
demonstrated that transfused blood may cause an increase in the
levels of lead and mercury14,15,45,68,69 in the blood of the recipients,
and even very small amounts of lead may have negative effects on
children.16,63
PFOS, PFOA, PFHxS, PFNA and PFDA serum concentrations in
the Norwegian donors were not higher than in previous studies of
blood donors in Germany, USA and South Korea (Table S3).21,22,24
Very few donors had concentrations of PFHxS, PFNA and PFDA over
the 97.5 percentile concentration of these PFAS in the adolescent
Norwegian population. However, the concentrations of the
recognised organic pollutants PFOS and PFOA were over the
suggested limits for donor blood (based on the 2018 EFSA TWIs) in
100% of donors. It is, however, unknown if few blood transfusions
with these concentrations of PFOS and PFOA may cause permanent
health damage in infants. The estimation of the acceptable venous
concentrations based on the oral TWIs for PFAS is not an optimal
approach as the number of transfusions during the week may vary.
The long-term health effects of these PFAS concentrations received
not as a chronic alimentary exposure, but with few blood transfusions,
are not known. Further research in this field is required.
We suggest that measures to limit the exposure of paediatric recip-
ients of blood products to heavy metals and other pollutants should be
evaluated by the appropriate regulatory bodies. The present work and
several other studies have shown that blood levels of environmental
pollutants tend to increase with the individual's age in cross-sectional
studies.17,49,70,71 Selecting young donors for transfusions to infants may
therefore be a feasible approach to reduce the risk of adverse health
effects. Our data showed that the optimal cut-off for donor's age for
selecting blood with the lowest lead concentrations was 22 years or
younger; this corresponds with the results from the study of Canadian
donors that suggested 23 years as a possible age cut-off.17 It may also
be appropriate to ask donors for known sources of exposure (eg, occu-
pational, special dietary habits, smoking etc.). However, the ultimate
precaution would be to measure heavy metal and other pollutant con-
centrations in donor blood before transfusions to premature infants and
other particularly vulnerable patients.
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